Boston College Law School
JD, 2006

Postdoctoral Associate, 2000
Biophysical Chemistry

Oxford University
DPhil, 1999
Biophysical Chemistry

Cambridge University
BA, 1996, First Class Honors
Natural Sciences



US District Court, Massachusetts

US Patent & Trademark Office



Publications & Events

Choate Honored for Excellence in Patent Law

Choate Named to IAM Patent 1000: The World’s Leading Patent Professionals for IP Prosecution, Transactions, and Litigation

Choate Partners Dr. Brenda Jarrell and Dr. Charles Lyon Named “Intellectual Property Trailblazers” by The National Law Journal

Six Intellectual Property Attorneys at Choate Named "IP Stars" for 2016 by Managing Intellectual Property

Charles Lyon, DPhil and Robert Sahr, PhD on FDA Regulation of Antibody Drug Conjugates

Choate Named to IAM Patent 1000: The World’s Leading Patent Practitioners for IP Prosecution, Transactions and Litigation

Choate's Intellectual Property Group Receives Top Rankings in Managing Intellectual Property's 2015 "IP Handbook"

Charles Lyon Speaks on Protecting Proprietary Technology in the US

Choate’s Intellectual Property Group Receives Top “Tier 1” Ranking in Managing Intellectual Property’s 2013 “IP Handbook”

Choate's Intellectual Property Group Named to IAM Patent 1000

Choate’s Intellectual Property Group Named to IAM Patent 1000

Charles Lyon Quoted on Gene Patentability in BioPharm Insight

Charles Lyon on Patent Drafting Pointers in Prometheus in Law360

Charles Lyon Named 2011 Up & Coming Lawyer

Is Ariad v Eli Lilly Good or Bad?

Charles Lyon Speaks on International IP

US Patent and Trademark Office to pilot accelerated review of green technology patents

Choate Announces Three New Partners

The Federal Circuit Clarifies Test for Patent Eligible Subject Matter of Method Claims

Charles E. Lyon, DPhil

Practice Group Leader

t 617-248-4793   f 617-248-4000

"has a keen understanding of how to evaluate intellectual property"

IAM Patent 1000

Charles Lyon, co-chair of the Intellectual Property group, focuses on helping clients understand, evaluate and respond to IP issues that arise in the context of business transactions or during the research and development of new products and technologies.  Dr. Lyon has led hundreds of IP due diligence reviews on behalf of investors, investment banks and life science companies.  Dr. Lyon also routinely provides advice and opinions regarding freedom-to-operate and IP landscape issues to assist with R&D decisions and in the context of pre-litigation disputes including Hatch-Waxman and Biosimilar litigationDr. Lyon is particularly sought after for his deep knowledge of the life sciences patent landscape and for his efficiency and ability to clearly communicate those issues that are most likely to affect the overall valuation of the underlying transaction or the risks associated with a particular IP dispute.  While he practices mostly in the life sciences sector, Dr. Lyon’s background as a chemist means that he is also routinely called upon by clients in the chemical industry.

He has been named “Intellectual Property Trailblazer” by The National Law Journal, a “Boston Rising Star” by the National Law Journal, an “Up & Coming Lawyer” by Massachusetts Lawyers Weekly and is named a Massachusetts Super LawyerDr. Lyon has been named a World’s Leading Patent Practitioner by IAM Patent 1000 and an “IP Star” by Managing Intellectual Property.

Practice Focus

IP Due Diligence & Landscape Analysis:  investor and company-side IP due diligence in the context of equity and debt financings, public offerings, mergers and acquisitions, collaborations, licenses and other transactions; landscape and freedom-to-operate analysis on behalf of investors and founders involved in company formations, or in the context of research and development planning and product clearances.

Intellectual Property Prosecution:  strategic development and management of complex patent portfolios with specific expertise in gene therapy, immunotherapies, recombinant proteins, small molecules, drug delivery, personalized medicine, diagnostic tests, polymer chemistry, nanoparticles and catalysis.

Intellectual Property Disputes:  counseling in the context of pre-litigation disputes including invalidity and non-infringement opinions and planning for post-grant challenges; assist in patent infringement cases within the life sciences and chemical industries.

Representative Engagements

IP Due Diligence & Landscape Analysis:

  • Assisted multinational healthcare company navigate numerous patent landscapes and license arrangements involving immuno and molecular based diagnostic products.
  • Due diligence and landscape analysis for financings of several leading biopharma companies developing gene therapies.
  • Due diligence and landscape analysis for investors prior to the formation of biopharma company developing gene editing technologies.      
  • Landscape analysis for biopharma company to support collaboration involving gene editing and immuno-oncology technologies.
  • Landscape analysis and legal opinions for biopharma company in preparation for launch of several biosimilar antibodies.
  • Landscape analysis for major pharmaceutical company evaluating partnerships in antibody-drug conjugate space.
  • Freedom-to-operate analysis for major healthcare company’s acquisition of foam technology for treatment of chronic wounds.
  • Landscape analysis to assist research and development of biopharma company’s antibody products.
  • Opinion work for animal health company relating to third party vaccine patents.
  • Due diligence for diagnostic company’s acquisition of company with diagnostic tests for various infectious agents.
  • Freedom-to-operate analysis for multinational diagnostic company in context of supply agreement for point-of-care diagnostic device.
  • Due diligence for pharmaceutical company’s acquisition of implant technologies for the treatment of pain and opioid abuse.      
  • Due diligence for investor with focus on therapeutics, diagnostics and medical devices used for treating and diagnosing cardiovascular diseases.
  • Due diligence for investment banks involved in numerous public offerings.

Intellectual Property Prosecution:

  • Helped build strategic patent portfolio for prognostic cancer tests.  Guided portfolio through two successive acquisitions by market leaders including most recent acquisition valued at about $580 million.
  • Represented pharmaceutical client from start-up phase through acquisition.  Built patent portfolio around glucose responsive insulin product for treatment of Type II diabetes.  Helped position company for acquisition with potential valuation of over $500 million.
  • Ongoing development and management of patent portfolio for chemical company developing catalysts and polymer technologies that can be used to produce green polymers.
  • Strategic patent portfolio development for immunotherapy company developing modified antibodies for use in treatment of cancer and infectious diseases.

Intellectual Property Disputes: 

  • Strategic planning and support of litigation for healthcare company selling newborn hearing screening tests.
  • Strategic planning and support of litigation for healthcare company enforcing patent for cancer diagnostic tests.
  • Successfully settled pre-litigation dispute involving immuno-based diagnostic tests for infectious agents.
  • Strategic planning and support of litigation for pharmaceutical companies in Hatch-Waxman litigation.

Professional and Community Involvement

Dr. Lyon was a peer reviewer for the Massachusetts Life Sciences Center Small Business Matching Grant Program.  Dr. Lyon is a member of the Boston Patent Law Association and the Boston Bar Association.  He is also a member of the Oxford and Cambridge Society of New England.



Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.